The approval of non-immunosuppressive and immunosuppressive novel therapies is revolutionizing the IgAN treatment landscape, which is rapidly evolving beyond traditional standard of care therapies like RAASi. Additionally, recent clinical evidence demonstrated the potential of combined therapies to maximize proteinuria reduction in alignment with evolving clinical practice guideline recommendations. This symposium delves into the latest advances in IgAN care, and case-based insights and practical strategies will be provided to highlight the critical need to achieve the lowest possible proteinuria levels in patients with IgAN and to optimize individualized patient care.
Click here to register for the ERA Congress.
The ERA assumes no responsibility for the information published on this website.
Revolutionizing IgAN Care in the Era of Precision Medicine: Diagnostic Approaches, Evolving Guidelines, and Novel Therapies
Emerging therapies are revolutionizing IgAN treatment. Our experts discuss the importance of timely diagnosis & details of new and upcoming therapies.
Bruno-Kreisky-Platz 1, 1220 Wien, Austria, Room B
Overview
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Prof Dr. Jörg Latus
Chief Physician
Department of Nephrology
Robert Bosch Hospital
Stuttgart, Germany
Dr. Latus has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alexion, AstraZeneca, Boehringer Ingelheim, CSL Vifor, Stada
Faculty:
Jürgen Floege, MD
Senior Professor
RWTH Aachen University Hospital
Aachen, Germany
Dr. Floege has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, Biogen, Boehringer, Calliditas, Chinook, CSL Vifor, Novartis, Omeros, Roche, Stadapharm, Travere, Vera Therapeutics
Other: Data Safety Monitoring Boards in studies of AstraZeneca
Michelle O’Shaughnessy, MD, MBBCh
Consultant Nephrologist
University of Galway
Galway, Ireland
Dr. O’Shaughnessy has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: CSL Vifor, Otsuka, Stada, Vera Therapeutics
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Kathleen Sheridan, PhD, has no relevant relationships to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Assess patients with suspected IgA nephropathy (IgAN) to reach a definitive diagnosis in a timely manner
- Apply the latest IgAN clinical practice guideline recommendations through case-based discussions
- Develop personalized treatment plans to optimize outcomes in patients with IgAN
Target Audience
This activity has been designed to meet the educational needs of nephrologists as well as all other physicians, nurse practitioners, nurses, and healthcare providers involved in managing patients with immunoglobulin A nephropathy (IgAN).
Accreditation and Credit Designation Statements
EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association, physicians may convert EBAC® CE credits/points to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit.
EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).
This live activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC) for 60 minutes of effective education time.
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from CSL Vifor.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Overview
The approval of non-immunosuppressive and immunosuppressive novel therapies is revolutionizing the IgAN treatment landscape, which is rapidly evolving beyond traditional standard of care therapies like RAASi. Additionally, recent clinical evidence demonstrated the potential of combined therapies to maximize proteinuria reduction in alignment with evolving clinical practice guideline recommendations. This symposium delves into the latest advances in IgAN care, and case-based insights and practical strategies will be provided to highlight the critical need to achieve the lowest possible proteinuria levels in patients with IgAN and to optimize individualized patient care.
Click here to register for the ERA Congress.
The ERA assumes no responsibility for the information published on this website.Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Prof Dr. Jörg Latus
Chief Physician
Department of Nephrology
Robert Bosch Hospital
Stuttgart, Germany
Dr. Latus has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alexion, AstraZeneca, Boehringer Ingelheim, CSL Vifor, Stada
Faculty:
Jürgen Floege, MD
Senior Professor
RWTH Aachen University Hospital
Aachen, Germany
Dr. Floege has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, Biogen, Boehringer, Calliditas, Chinook, CSL Vifor, Novartis, Omeros, Roche, Stadapharm, Travere, Vera Therapeutics
Other: Data Safety Monitoring Boards in studies of AstraZeneca
Michelle O’Shaughnessy, MD, MBBCh
Consultant Nephrologist
University of Galway
Galway, Ireland
Dr. O’Shaughnessy has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: CSL Vifor, Otsuka, Stada, Vera Therapeutics
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Kathleen Sheridan, PhD, has no relevant relationships to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Assess patients with suspected IgA nephropathy (IgAN) to reach a definitive diagnosis in a timely manner
- Apply the latest IgAN clinical practice guideline recommendations through case-based discussions
- Develop personalized treatment plans to optimize outcomes in patients with IgAN
Target Audience
This activity has been designed to meet the educational needs of nephrologists as well as all other physicians, nurse practitioners, nurses, and healthcare providers involved in managing patients with immunoglobulin A nephropathy (IgAN).
Accreditation and Credit Designation Statements
EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association, physicians may convert EBAC® CE credits/points to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit.
EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).This live activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC) for 60 minutes of effective education time.
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from CSL Vifor.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Recommended
Pearls of Wisdom: Optimizing Hyperkalemia Management in Patients with CKD
Pearls of Wisdom: Optimizing Hyperkalemia Management in Patients with CKD
CME/CEPearls of Wisdom: Optimizing Hyperkalemia Management in Patients with CKD
0.25 credits
Matthew R. Weir, MD
Nihar Desai, MD
Ellie Kelepouris, MD, FACP, FAHA
0.25 creditsDon't Miss It! Rapid & Accurate AAV Diagnosis
Don't Miss It! Rapid & Accurate AAV Diagnosis
MinuteCE®Don't Miss It! Rapid & Accurate AAV Diagnosis
0.75 program creditsSilke R. Brix, MD, MRCP, SCPR
Andreas Kronbichler, MD
0.75 program creditsOptimizing AAV Outcomes: Maintenance Therapies
Optimizing AAV Outcomes: Maintenance Therapies
MinuteCE®Optimizing AAV Outcomes: Maintenance Therapies
0.75 program creditsBernhard Hellmich, MD
Silke R. Brix, MD, MRCP, SCPR
0.75 program creditsImplementing the SOC Induction Therapies in AAV
Implementing the SOC Induction Therapies in AAV
MinuteCE®Implementing the SOC Induction Therapies in AAV
0.75 program creditsSilke R. Brix, MD, MRCP, SCPR
Bernhard Hellmich, MD
0.75 program credits